Abbreviations

†In PARAGON-HF, HFpEF was defined as LVEF ≥45% with structural heart disease(LAE or LVH) and no prior echocardiographic LVEF <40%. Median LVEF was 57%.6 In a prespecified subgroup analysis of patients with LVEF at or below the median, ENTRESTO reduced the rate of total HF hospitalization and CV death vs valsartan, driven by reduction in HF hospitalization: RR 0.78 (95% CI: 0.64–0.95); ARR 3.6. HF hospitalization component: RR 0.75 (95% CI: 0.60–0.95); ARR 3.6. CV death component: HR 0.99 (95% CI: 0.77–1.26); ARR 0.1.
*NYHA Class II–III patients with HFrEF.
‡In NYHA Class II–III HFrEF patients who tolerate an ACEi/ARB.
ACC: American College of Cardiology; AHA: American Heart Association; ARR: absolute rate reduction; HFrEF: Heart Failure with reduced ejection fraction;HFmrEF : Heart Failure with mildly reduced ejection fraction; HFpEF: Heart Failure with preserved ejection fraction; HF: Heart Failure; HFSA, Heart Failure Society of America; LAE: left atrial enlargement; LVH, left ventricular hypertrophy; RR, rate ratio.